You Saved or subscribe to save 5%
By inhibiting DPP-4, these drugs prolong incretin activity, leading to: Glucose-dependent insulin secretion from beta cells Suppression of glucagon from alpha cells Improved postprandial blood glucose control This mechanism does not stimulate insulin release in absence of glucose, making hypoglycemia rare
doi:10.1016/j.medj.2025.100645 22
adults, and a rapidly rising number of IVF patients, now take semaglutide, tirzepatide, or related agents [2]
eLife 12 , RP88742 (2024)
Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes